ArticleFoods (Basel, Switzerland)2026
The Citrus Flavonoid Naringin Confers Neuroprotection Against Cerebral Ischemia by Enhancing Endogenous Antioxidant Capacity and Suppressing Neuroinflammation.
Article in Foods (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Naringin is a naturally occurring flavanone glycoside found in citrus fruits that has been widely studied for its antioxidant and anti-inflammatory activities. The precise mechanisms by which naringin exerts protective effects against ischemic stroke are not yet fully understood. To address this gap, the current study examined the efficacy of naringin administration (100 mg/kg BW) in an experimental rat model involving permanent right middle cerebral artery occlusion (Rt.MCAO). Administration of naringin significantly improved neurological performance while reducing cerebral infarct volume and brain edema following ischemic injury. Histopathological evaluation further demonstrated that naringin preserved neuronal density in the cerebral cortex and hippocampus, indicating protection against ischemia-induced neuronal degeneration. In parallel, naringin attenuated glial activation, as evidenced by reduced expression of ionized calcium-binding adapter molecule 1 (Iba1) and glial fibrillary acidic protein (GFAP), accompanied by suppression of the pro-inflammatory mediators interleukin-6 (IL-6) and cyclooxygenase-2 (COX-2). Furthermore, naringin restored redox homeostasis by lowering malondialdehyde (MDA) levels and preserving the activities of the endogenous antioxidant enzymes catalase (CAT), glutathione peroxidase (GSH-Px), superoxide dismutase (SOD), and mitochondrial superoxide dismutase (mitochondrial SOD). A significant reduction in myeloperoxidase (MPO) activity further supported its ability to alleviate oxidative stress and inflammatory responses. Our findings indicate that naringin has neuroprotective effects in experimental ischemic stroke. These effects were associated with improved antioxidant defenses and reduced neuroinflammatory responses. However, further preclinical studies are needed to confirm the underlying mechanisms, optimal treatment conditions, and long-term effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.